“Our ability to use proteomic signatures to predict cardiovascular risk continues to expand, and may become available to a broad cohort of patients in the future,” Dr. Sherwood said. “The clinical utility of these platforms remains uncertain, and further investigation is needed to determine if proteomic based risk scores could help to modify therapeutic management in lower risk populations.”
SomaLogic provided funding for protein assays and employed two coauthors. Four coauthors and the editorialist reported disclosures.
SOURCE: http://bit.ly/28L6oEy and http://bit.ly/28NgaJg
JAMA 2016.